Longitudinal Study on Low-Dose Aspirin versus Placebo Administration in Silent Brain Infarcts: The Silence Study.
Ilaria MaestriniMarta AltieriLaura Di ClementeEdoardo VicenziniPatrizia PantanoEytan RazMauro SilvestriniLeandro ProvincialiIsabella PaolinoCarmine MariniMatteo Di GiuseppeTommasina RussoFrancesco FedericoCristiana CoppolaMaria Pia PronteraDomenico Maria MezzapesaVincenzo LuciveroLucilla ParnettiPaola SarchielliMaria PeducciDomenico InzitariGiovanna CarlucciCarlo SerratiCarla ZatAnna CavalliniAlessandra PersicoGiuseppe MicieliStefano BastianelloVittorio DI PieroPublished in: Stroke research and treatment (2018)
These data show an increase of new CVD events in the untreated group. Despite the study limitations, SBI seems to be a negative prognostic factor and ASA preventive treatment might improve SBI prognosis. EU Clinical trial is registered with EudraCT Number: 2005-000996-16; Sponsor Protocol Number: 694/30.06.04.
Keyphrases
- low dose
- clinical trial
- prognostic factors
- randomized controlled trial
- double blind
- type diabetes
- high dose
- cardiovascular disease
- coronary artery disease
- electronic health record
- cardiovascular events
- combination therapy
- big data
- acute coronary syndrome
- artificial intelligence
- blood brain barrier
- phase ii
- subarachnoid hemorrhage